Treatment of chronic renal failure
119 results
1 - 100Treatment of chronic renal failure
Safe use of non-steroidal anti-inflammatory drugs (NSAIDs)
Anaemia of chronic disease (ACD)
Drug treatment for hypertension
Proteinuria
Chronic heart failure
Erythropoietin for chronic renal failure anaemia
ARB treatment of high CV risk patients
IgA nephropathy
Growth hormone for children with chronic renal failure
Curable causes of cognitive challenges and memory disease
Hypocalcaemia, hypoparathyroidism and vitamin D deficiency
Hyperglycaemic hyperosmolar syndrome
Acute kidney injury
Organ transplant recipient in primary health care
Secondary hypertension
Glomerulonephrites
Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis
Increased blood creatinine concentration, eGFR and renal function tests
Eye symptoms and signs of systemic diseases
Hyperkalaemia
No benefit to addition of stenting for treatment of atherosclerotic renal artery stenosis
Polycystic kidney disease
Short-bowel syndrome
Gout and pseudogout
Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease: Cochrane systematic review
Furosemide to prevent or treat acute renal failure in adults
Cirrhosis of the liver
Finerenone decreases hospitalization for heart failure in patients with type 2 diabetes and chronic kidney disease (NNT = 189/year)
Diabetic kidney disease (diabetic nephropathy)
Elevated blood pressure in pregnancy (gestational hypertension, pre-eclampsia)
Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia
Dronedarone in the prevention of atrial fibrillation - Image
Skin colour changes and pigmentary disorders
Tumours of haematopoietic and lymphoid tissues: general information
Endovascular versus open surgical repair for complicated chronic Type B aortic dissection
High-dose B-vitamins harmful to patients with diabetic nephropathy
Statins for people with chronic kidney disease not requiring dialysis
Schistosomiasis (bilharziasis)
Interventions for chronic kidney disease in people with sickle cell disease
Statins for improving renal outcomes
SGLT-2 inhibitors and GLP-1 agonists for diabetes and chronic kidney disease
IV iron improves symptoms in chronic heart failure patients with iron deficiency
Obstipation in the adult
Pruritus
Nephrotic syndrome
Hypernatraemia
More evidence against antibiotics for acute asthma exacerbations
Drugs commonly causing poisonings
Emergency interventions for hyperkalaemia
Erythropoiesis‐stimulating agents for anaemia in chronic heart failure patients
Hypertension in elderly patients
Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults
Interventions for managing taste disturbances
Early treatment with ACE inhibitors in acute myocardial infarction
Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants
SBP of 120 instead of 140 in nondiabetic, high-risk elderly leads to significant benefits and some harms (SPRINT)
Hypertension: investigations, treatment initiation and non-pharmacological treatment
Antitubercular medication in ambulatory care
Hypoglycaemia in the absence of diabetes in adults
Continuous infusion versus bolus injection of loop diuretics for acute heart failure
Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants
Chronic diseases and pregnancy
Adder (Vipera berus) bite
Interventions for metabolic bone disease in children with chronic kidney disease
Higher hemoglobin target with epoeitin alfa is harmful in CKD (CHOIR)
Guidelines for when to consider mortality-reducing treatments for patients with type 2 diabetes
SGLT-2 inhibitors in type 2 diabetes
Palliative treatment
High-dose barium enemas prevent recurrent diverticular bleeding
Nipple discharge and mastitis in a non-lactating woman
Antidepressants for depression in physical illness
Oral adsorbents for preventing or delaying the progression of chronic kidney disease
Oral antidiabetic drugs and GLP-1 analogues
Rosuvastatin does not improve outcomes in HF with average lipids
Normal and abnormal growth in childhood
Glucagon-like peptide analogues (GLP-1 analogues) for type 2 diabetes
Urinary tract infections